A physicist by training, with a PhD in Molecular Biophysics from Karolinska Institutet and a career at Government Agencies such as Vinnova and the Ministry of Enterprise and Innovation as well as the Royal Academy of Engineering Sciences, Anna Sandström is today Science Policy and Relations Director Europe at AstraZeneca. Her role includes to catalyse new R&D collaborations with academia, companies and third-party groups and to contribute to life science polices spurring a vibrant and internationally competitive innovation system in EU, UK and Sweden.
Anna Sandström is board member of for instance the Royal Institute of Technology, the MaxIV synchrotron X-ray source and the Drug Discovery and Development platform at the Science for Life Laboratory as well as heading the R&D committee at the trade body SwedenBIO.
AstraZeneca is a global, science-led, innovative biopharmaceutical business, with 61,100 employees of which 8,300 in R&D. AstraZeneca annually invests about 26 % of the revenue in R&D, in 2017 corresponding to 5.8 bnUSD. AstraZeneca has three strategic R&D centres of which two are found in Europe, in Gothenburg Sweden and Cambridge UK, the third centre is located in Gaithersburg USA.